Lori A Daiello1, Assawin Gongvatana2, Shira Dunsiger3, Ronald A Cohen2, Brian R Ott4. 1. Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA; Alzheimer's Disease and Memory Disorders Center, Rhode Island Hospital, Providence, RI, USA. Electronic address: Lori_Daiello@brown.edu. 2. Department of Psychiatry and Human Behavior, Warren Alpert Medical School of Brown University, Providence, RI, USA. 3. Department of Behavior and Social Sciences, The Miriam Hospital, Providence, RI, USA. 4. Department of Neurology, Warren Alpert Medical School of Brown University, Providence, RI, USA; Alzheimer's Disease and Memory Disorders Center, Rhode Island Hospital, Providence, RI, USA.
Abstract
OBJECTIVE: The aim of this study was to investigate whether the use of fish oil supplements (FOSs) is associated with concomitant reduction in cognitive decline and brain atrophy in older adults. METHODS: We conducted a retrospective cohort study to examine the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative and indicators of cognitive decline. Older adults (229 cognitively normal individuals, 397 patients with mild cognitive impairment, and 193 patients with Alzheimer's disease) were assessed with neuropsychological tests and brain magnetic resonance imaging every 6 months. Primary outcomes included (1) global cognitive status and (2) cerebral cortex gray matter and hippocampus and ventricular volumes. RESULTS: FOS use during follow-up was associated with significantly lower mean cognitive subscale of the Alzheimer's Disease Assessment Scale and higher Mini-Mental State Examination scores among those with normal cognition. Associations between FOS use and the outcomes were observed only in APOE ε4-negative participants. FOS use during the study was also associated with less atrophy in one or more brain regions of interest.
OBJECTIVE: The aim of this study was to investigate whether the use of fish oil supplements (FOSs) is associated with concomitant reduction in cognitive decline and brain atrophy in older adults. METHODS: We conducted a retrospective cohort study to examine the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative and indicators of cognitive decline. Older adults (229 cognitively normal individuals, 397 patients with mild cognitive impairment, and 193 patients with Alzheimer's disease) were assessed with neuropsychological tests and brain magnetic resonance imaging every 6 months. Primary outcomes included (1) global cognitive status and (2) cerebral cortex gray matter and hippocampus and ventricular volumes. RESULTS:FOS use during follow-up was associated with significantly lower mean cognitive subscale of the Alzheimer's Disease Assessment Scale and higher Mini-Mental State Examination scores among those with normal cognition. Associations between FOS use and the outcomes were observed only in APOE ε4-negative participants. FOS use during the study was also associated with less atrophy in one or more brain regions of interest.
Authors: G L Bowman; L C Silbert; D Howieson; H H Dodge; M G Traber; B Frei; J A Kaye; J Shannon; J F Quinn Journal: Neurology Date: 2011-12-28 Impact factor: 9.910
Authors: Alan D Dangour; Peter J Whitehouse; Kevin Rafferty; Stephen A Mitchell; Lesley Smith; Sophie Hawkesworth; Bruno Vellas Journal: J Alzheimers Dis Date: 2010 Impact factor: 4.472
Authors: Owen Carmichael; Christopher Schwarz; David Drucker; Evan Fletcher; Danielle Harvey; Laurel Beckett; Clifford R Jack; Michael Weiner; Charles DeCarli Journal: Arch Neurol Date: 2010-11
Authors: P Barberger-Gateau; C Raffaitin; L Letenneur; C Berr; C Tzourio; J F Dartigues; A Alpérovitch Journal: Neurology Date: 2007-11-13 Impact factor: 9.910
Authors: Yuhai Zhao; Frederic Calon; Carl Julien; Jeremy W Winkler; Nicos A Petasis; Walter J Lukiw; Nicolas G Bazan Journal: PLoS One Date: 2011-01-05 Impact factor: 3.240
Authors: Ondine van de Rest; Yamin Wang; Lisa L Barnes; Christine Tangney; David A Bennett; Martha Clare Morris Journal: Neurology Date: 2016-05-04 Impact factor: 9.910
Authors: Robert K McNamara; Ruth H Asch; Diana M Lindquist; Robert Krikorian Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2017-05-09 Impact factor: 4.006
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Martha Clare Morris; John Brockman; Julie A Schneider; Yamin Wang; David A Bennett; Christy C Tangney; Ondine van de Rest Journal: JAMA Date: 2016-02-02 Impact factor: 56.272
Authors: Hussein N Yassine; Meredith N Braskie; Wendy J Mack; Katherine J Castor; Alfred N Fonteh; Lon S Schneider; Michael G Harrington; Helena C Chui Journal: JAMA Neurol Date: 2017-03-01 Impact factor: 18.302